Ariad Pharmaceuticals (ARIA) Q2 2012 Earnings Call August 02, 2012 8:30 am ET Executives Maria E. Cantor - Senior Vice President of Corporate Affairs Harvey J. Berger - Principal Founder, Chairman of the Board, Chief Executive Officer, President and Chairman of Executive Committee Edward M. Fitzgerald - Chief Financial Officer, Principal Accounting Officer, Executive Vice President and Treasurer Analysts Matthew Harrison - UBS Investment Bank, Research Division Y. Katherine Xu - William Blair & Company L.L.C., Research Division Ryan Martins - Lazard Capital Markets LLC, Research Division Michael J. Yee - RBC Capital Markets, LLC, Research Division Joel D. Sendek - Stifel, Nicolaus & Co., Inc., Research Division Eileen Flowers - Jefferies & Company, Inc., Research Division Ying Huang - Barclays Capital, Research Division Michael G. King - Rodman & Renshaw, LLC, Research Division Philip Nadeau - Cowen and Company, LLC, Research Division Howard Liang - Leerink Swann LLC, Research Division Karen E. Jay - JP Morgan Chase & Co, Research Division Rachel L. McMinn - BofA Merrill Lynch, Research Division Echo Yinghui He - Maxim Group LLC, Research Division PresentationOperator
Thank you for holding for ARIAD Pharmaceuticals Second Quarter 2012 Investor Conference Call. [Operator Instructions] Please be advised that this call is being taped at the company's request and will be archived on the company's website for 3 weeks from today. At this time, I'd like to introduce Ms. Maria Cantor, ARIAD's Senior Vice President, Corporate Affairs. Please go ahead. Maria E. Cantor Good morning, and thank you for joining us. This morning, we report on financial results and corporate developments for the second quarter of 2012. Dr. Harvey Berger, our Chairman and Chief Executive Officer; and Mr. Ed Fitzgerald, our Executive Vice President and Chief Financial Officer are joining me on this call.